Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 29, 2024 - Issue 1
Submit an article Journal homepage
1,133
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How will tovorafenib change our treatment of pediatric low-grade glioma?

Inci Yamana The Hospital for Sick Children, 55 University Avenue, Toronto, CanadaView further author information
&
Eric Bouffeta The Hospital for Sick Children, 55 University Avenue, Toronto, Canada;b Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6832-6539View further author information
ORCID Icon
Pages 1-3 | Received 13 Nov 2023, Accepted 29 Jan 2024, Published online: 02 Feb 2024

References

  • Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: Current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017 Jul 20;35(21):2370–2377. doi: 10.1200/JCO.2017.73.0242
  • de Blank P, Bandopadhayay P, Haas-Kogan D, et al. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019 Feb;31(1):21–27. doi: 10.1097/MOP.0000000000000717
  • Fried I, Tabori U, Tihan T, et al. Optic pathway gliomas: a review. CNS Oncol. 2013 Mar;2(2):143–159. doi: 10.2217/cns.12.47
  • Jain P, Silva A, Han HJ, et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget. 2017 Oct 17;8(49):84697–84713. doi: 10.18632/oncotarget.20949
  • Sun Y, Alberta JA, Pilarz C, et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 Jun 1;19(6):774–785. doi: 10.1093/neuonc/now261
  • Tkacik E, Li K, Gonzalez-Del Pino G, et al. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J Biol Chem. 2023 May;299(5):104634. doi: 10.1016/j.jbc.2023.104634
  • Offer K, McGuire MT, Song K, et al. Activity of type II RAF inhibitor tovorafenib in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion. JCO Precis Oncol. 2023 Jul;7(7):e2300065. doi: 10.1200/PO.23.00065
  • Rasco DW, Medina T, Corrie P, et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2023 Jul;92(1):15–28. doi: 10.1007/s00280-023-04544-5
  • Wright KK, Greenspan E. Phase I study of DAY101 (TAK580) in children and young adults with radiographically recurrent or progressive low-grade glioma. Neuro Oncol. 2020;22(Supplement_3):iii304–iii304. doi: 10.1093/neuonc/noaa222.126
  • Wright K, Kline C, Abdelbaki M. PNOC014: phase IB study results of DAY101(tovorafenib) for children with low-grade gliomas (LGGs) and other RAS/RAF/MEK/ERK pathway-activated tumors. Neuro Oncol. 2022;24(Supplement_7):vii84–vii84. doi: 10.1093/neuonc/noac209.318
  • Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2023 Nov 17;30(1):207–217. doi: 10.1038/s41591-023-02668-y
  • Van Tilburg CJDS, Avula R, Schouten-van Meeteren S, et al. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. Neuro Oncol. 2022;24(Supplement_7):vii77–vii78. doi: 10.1093/neuonc/noac209.295

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.